Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis
Phase 2
Active, not recruiting
215
2026-06
Industry sponsor intelligence
Hanmi Pharmaceutical Company LimitedClinical Pipeline.
Lead-sponsor view of Hanmi Pharmaceutical Company Limited's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 0
- Active
- 1
- Completed
- 3
- Results posted
- 3
- Avg enrollment
- 182
Pipeline overview
Programs by phase and activity.
Velocity
Hanmi Pharmaceutical Company Limited trials by start year
Study start year · indexed snapshot
Development
Trials by phase
4phase labels
Early Phase 10
Phase 12
Phase 21
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Efpeglenatide → | 1 | 0 | 0 | 1 | 0 | 0 |
| Efocipegtrutide → | 3 | 2 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Hanmi Pharmaceutical Company Limited · Obesity
Phase 1
Completed
41
2025-02
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
Hanmi Pharmaceutical Company Limited · NAFLD
Phase 1
Completed
66
2025-01
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Hanmi Pharmaceutical Company Limited · Type 2 Diabetes Mellitus
Phase 3
Completed
406
2022-01
Search sponsor records
All Hanmi Pharmaceutical Company Limited studies.
This page groups studies where Hanmi Pharmaceutical Company Limited is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT04505436Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in SubjectsJun 30, 2026NCT03374241A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)Feb 6, 2025NCT03744182A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDJan 27, 2025NCT03353350Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseJan 18, 2022